Author(s):
Vaibhav Sawale, Prafulla Sabale, Komal Somkuwar, Rina Ikhar, Vidya Sabale
Email(s):
vaibhavsawale33@gmail.com
DOI:
10.52711/0974-360X.2025.00213 
Address:
Vaibhav Sawale1*, Prafulla Sabale1, Komal Somkuwar1, Rina Ikhar1, Vidya Sabale2
1Department of Pharmaceutical Sciences, R.T.M. Nagpur University, Mahatma Jyotiba Fuley Educational Campus, Amravati Road, Nagpur - 440033, Maharashtra, India.
2Dadasaheb Balpande College of Pharmacy, Besa, Nagpur - 440037, Maharashtra, India.
*Corresponding Author
Published In:
Volume - 18,
Issue - 4,
Year - 2025
ABSTRACT:
A novel RP-HPLC method was established for quantifying Doravirine and its tablet formulation. The chromatographic conditions were optimized to effectively separate Doravirine using a Shim-Pack Solar C18 column (4.6x250mm) with a 5µm particle size. The flow rate was maintained at 1.0ml/min, and the mobile phase was a 60:40% v/v mixture of acetonitrile and water. Doravirine detection occurred at 324 nm. The HPLC system included a Shimadzu HPLC Auto Sampler, a DGU-20A5R separation module, a photodiode array detector, and lab solution software. Doravirine had a retention time of 4.920 minutes and a purity of 98.56%. System suitability parameters, such as theoretical plates (5349) and tailing factor (1.142), were evaluated. The method was validated according to ICH guideline Q2(R1) for accuracy, precision, specificity, linearity, and robustness, and to determine the limits of detection (LOD) and quantification (LOQ). The method proved to be simple, accurate, rapid, and precise for assessing Doravirine and its formulation.
Cite this article:
Vaibhav Sawale, Prafulla Sabale, Komal Somkuwar, Rina Ikhar, Vidya Sabale. Development and Validation of RP-HPLC Method for the Quantification of Doravirine in Bulk and Tablet Formulation. Research Journal of Pharmacy and Technology. 2025;18(4):1486-0. doi: 10.52711/0974-360X.2025.00213
Cite(Electronic):
Vaibhav Sawale, Prafulla Sabale, Komal Somkuwar, Rina Ikhar, Vidya Sabale. Development and Validation of RP-HPLC Method for the Quantification of Doravirine in Bulk and Tablet Formulation. Research Journal of Pharmacy and Technology. 2025;18(4):1486-0. doi: 10.52711/0974-360X.2025.00213 Available on: https://rjptonline.org/AbstractView.aspx?PID=2025-18-4-4
REFERENCES:
1. Sabale PM, Damor JS, Chudasama G. Development and validation of RP-HPLC method for simultaneous estimation of sparfloxacin and dexamethasone in bulk and pharmaceutical dosage form. Res J Pharm Technol. 2013; Jul; 6(7): 780-3.
2. Sabale PM, Chavda J, Sabale V. Simple spectrophotometric methods for the determination of Zn-sparfloxacin 1, 10-phenanthroline metal complex. Res J Pharm Technol. 2013; Jun; 6(6): 614-7.
3. Sable PM, Chudasama G, Patel CK, Sabale V. Studies in prospective process validation of fluconazole tablet dosage form. Res J Pharm Technol. 2014; Jan; 7(1): 52-8.
4. Namasivayam V, Vanangamudi M, Kramer VG, Kurup S, Zhan P, Liu X, Kongsted J, Byrareddy SN. The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic. J Med Chem. 2019; 62(10): 4851-4883. doi:10.1021/acs.jmedchem.8b00843
5. Khalilieh S, Yee KL, Sanchez R, Stoch SA, Wenning L, Iwamoto M. Clinical Pharmacokinetics of the Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor Doravirine: An Assessment of the Effect of Patient Characteristics and Drug–Drug Interactions. Clin Drug Investig. 2020; 40(10): 927-946. doi:10.1007/s40261-020-00934-2
6. Behm MO, Yee KL, Liu R, Levine V, Panebianco D, Fackler P. The Effect of Food on Doravirine Bioavailability: Results from Two Pharmacokinetic Studies in Healthy Subjects. Clin Drug Investig. 2017; 37(6): 571-579. doi:10.1007/s40261-017-0512-5
7. Nyamweya S, Hegedus A, Jaye A, Rowland-Jones S, Flanagan KL, Macallan DC. Comparing HIV-1 and HIV-2 infection: Lessons for viral immunopathogenesis. Rev Med Virol. 2013; 23(4): 221-240. doi:10.1002/rmv.1739
8. Somkuwar K, Sabale P, Sawale V, Rahangdale P. Method Development and Validation for the Estimation of Umifenovir in Bulk and Tablet Formulation by UV-Spectrophotometric and RP-HPLC. Research Journal of Pharmacy and Technology. 2024; Mar 31; 17(3): 1308-13.
9. Suneetha A, Priyadarshini GI, Mounika V, Aparna G. Development and Validation of RP-HPLC Method for the Estimation of Doravirine in Bulk and Pharmaceutical Dosage Form. Asian J Res Med Pharm Sci. 2021; 10(4): 26-31. doi:10.9734/ajrimps/2021/v10i430174
10. Kokkirala TK, Kancherla P, Alegete P, Suryakala D. A simple alternative and improved HPLC method for the estimation of doravirine, lamivudine, and tenofovir disoproxil fumarate in solid oral dosage form. Biomed Chromatogr. 2021; 35(8): 1-11. doi:10.1002/bmc.5121
11. Priyadarshini GI, Harish K. Method Development and Validation for the Simultaneous Estimation of Doravirine, Lamivudine and Tenofovir Bulk and Pharmaceutical Dosage form. 2021; 6(5): 1272-1284. doi:10.35629/7781-060512721284
12. Damle MC, Khairnar R. Hptlc Method for Simultaneous Estimation of Lamivudine, Tenofovir Disoproxil Fumarate, and Doravirine. Int J Pharm Pharm Sci. 2023; 15(9): 42-49. doi:10.22159/ijpps.2023v15i9.48681
13. Addanki S, Kuber BR. A new stability indicating RP-UPLC method for simultaneous estimation of Doravirine, Lamivudine and Tenofovir disoproxil fumarate in bulk and their combined pharmaceutical formulation. Future J Pharm Sci. 2021; 7(1). doi:10.1186/s43094-021-00349-6
14. Banothu Bhadru, V.Venkata Rao, Suryadevara Vidyadhara. Development And Validation Of Sensitive LC-MS/MS Method For Determination Of Doravirine In Human Plasma Samples. Int J Life Sci Pharma Res. 2022; 10(3): 29-35. doi:10.22376/ijpbs/lpr.2020.10.3.p29-35
15. Guidance for Industry Q2B Validation of Analytical Procedures: Methodology. U.S. Department of Health and Human Services; 1996. Available at: http://www.fda.gov/cder/guidance/index.htm
16. Harron DWG. Technical Requirements for Registration of Pharmaceuticals for Human Use: The ICH Process. In: The Textbook of Pharmaceutical Medicine. 2013: 447-460. doi:10.1002/9781118532331.ch23